Mast cells: Effector cells of anaphylaxis

Anaphylaxis and Hypersensitivity Reactions

Volumn , Issue , 2011, Pages 47-68

  Tsai, Mindy ^a   Galli, Stephen J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen; Basophils; c Kit; Degranulation; Histamine; IgE; IgG1; Mast cells; Mast cell deficient mice; Passive cutaneous anaphylaxis; Platelet activating factor; Sphingosine 1 phosphate; Stem cell factor

Indexed keywords

EID: 84885824776     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-951-2_4     Document Type: Chapter

References (161)

1. Bochner BS, Lichtenstein LM. Anaphylaxis. N Engl J Med. 1991;324:1785-1790.
2. Galli SJ. Pathogenesis and management of anaphylaxis: current status and future challenges. J Allergy Clin Immunol. 2005;115:571-574.
3. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115:584-591.
4. Simons FE. 9. Anaphylaxis. J Allergy Clin Immunol. 2008;121:S402-407; quiz S420.
5. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120:506-515; quiz 516-507.
6. 1-dependent passive anaphylaxis. J Clin Invest. 1997;99:901-914.
7. Strait RT, Morris SC, Yang M, Qu XW, Finkelman FD. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol. 2002;109:658-668.
8. Tsujimura Y, Obata K, Mukai K, et al. Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity. 2008;28:581-589.
9. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391-397.
10. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120:S2-24.
11. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749-786.
12. Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas. 2004;16:120-124.
13. Levy JH. Biomarkers in the diagnosis of anaphylaxis: making nature disclose her mysteries. Clin Exp Allergy. 2009;39:5-7.
14. Ono E, Taniguchi M, Mita H, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy. 2009;39:72-80.
15. Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8:310-315.
16. Kalesnikoff J, Galli SJ. Anaphylaxis: mechanisms of mast cell activation. Chem Immunol Allergy. 2010;95: 45-66.
17. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol. 1989;7:59-76.
18. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77:1033-1079.
19. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002;2:773-786.
20. Tsai M, Shih LS, Newlands GF, et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J Exp Med. 1991;174:125-131.
21. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8:478-486.
22. Miller HR, Wright SH, Knight PA, Thornton EM. A novel function for transforming growth factor-beta1: upregulation of the expression and the IgE-independent extracellular release of a mucosal mast cell granule-specific beta-chymase, mouse mast cell protease-1. Blood. 1999;93:3473-3486.
23. Ryan JJ, Kashyap M, Bailey D, et al. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol. 2007;27:15-32.
24. Irani AM, Craig SS, DeBlois G, Elson CO, Schechter NM, Schwartz LB. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol. 1987;138:4381-4386.
25. Bannert N, Farzan M, Friend DS, et al. Human mast cell progenitors can be infected by macrophagetropic human immunodeficiency virus type 1 and retain virus with maturation in vitro. J Virol. 2001;75:10808-10814.
26. Li Y, Li L, Wadley R, et al. Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4. Blood. 2001;97:3484-3490.
27. Sundstrom JB, Ellis JE, Hair GA, et al. Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood. 2007;109:5293-5300.
28. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000;173:131-140.
29. Grimbaldeston MA, Metz M, Yu M, Tsai M, Galli SJ. Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol. 2006;18:751-760.
30. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol. 2007;19:31-38.
31. Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304-328.
32. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9:1215-1223.
33. Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol. 2004;25:266-273.
34. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6:135-42.
35. Sayed BA, Brown MA. Mast cells as modulators of T-cell responses. Immunol Rev. 2007;217:53-64.
36. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007;217:65-78.
37. Wastling JM, Knight P, Ure J, et al. Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the beta-chymase, mouse mast cell protease-1. Am J Pathol. 1998;153:491-504.
38. Knight PA, Wright SH, Lawrence CE, Paterson Y Y, Miller HR. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J. Exp. Med. 2000;192:1849-1856.
39. Lawrence CE, Paterson YY, Wright SH, Knight PA, Miller HR. Mouse mast cell protease-1 is required for the enteropathy induced by gastrointestinal helminth infection in the mouse. Gastroenterology. 2004;127:155-165.
40. Tchougounova E, Pejler G, Abrink M. The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med. 2003;198:423-431.
41. Magnusson SE, Pejler G, Kleinau S, Abrink M. Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. FASEB J. 2009;23:875-882.
42. Abonia JP, Friend DS, Austen WG Jr, et al. Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. J Immunol. 2005;174:7285-7291.
43. Thakurdas SM, Melicoff E, Sansores-Garcia L, et al. The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. J Biol Chem. 2007;282:20809-20815.
44. Shin K, Watts GF, Oettgen HC, et al. Mouse mast cell tryptase mMCP-6 is a critical link between adaptive and innate immunity in the chronic phase of Trichinella spiralis infection. J Immunol. 2008;180:4885-4891.
45. McNeil HP, Shin K, Campbell IK, et al. The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum. 2008;58:2338-2346.
46. Feyerabend TB, Hausser H, Tietz A, et al. Loss of histochemical identity in mast cells lacking carboxypeptidase A. Mol Cell Biol. 2005;25:6199-6210.
47. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald HR. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med. 2007;204:2629-2639.
48. v mice and their increase by bone marrow transplantation. Blood. 1978;52:447-452.
49. sh) at the W-locus and a spontaneous recessive lethal in mice. Genet Res. 1982;39:315-322.
50. v mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med. 1985;162:1025-1043.
51. W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005;167:835-848.
52. W-sh sash mice. Clin Exp Allergy. 2005;35:82-88.
53. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol. 1994;55:1-96.
54. Duttlinger R, Manova K, Chu T Y, et al. W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development. 1993;118:705-717.
55. sh mutation on mouse chromosome 5 is associated with an inversion. Hum Mol Genet. 1995;4:2073-2079.
56. 57, and Ph Kit expression mutations define tissue-specific control elements located between-23 and-154 kb upstream of Kit. Blood. 1999;94:2658-2666.
57. sh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol. 2008;173:1693-1701.
58. Tsai M, Wedemeyer J, Ganiatsas S, Tam S Y, Zon LI, Galli SJ. In vivo immunological function of mast cells derived from embryonic stem cells: an approach for the rapid analysis of even embryonic lethal mutations in adult mice in vivo. Proc Natl Acad Sci USA. 2000;97:9186-9190.
59. Metz M, Piliponsky AM, Chen CC, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science. 2006;313:526-530.
60. Scholten J, Hartmann K, Gerbaulet A, et al. Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res. 2008;17:307-315.
61. Musch W, Wege AK, Mannel DN, Hehlgans T. Generation and characterization of alpha-chymase-Cre transgenic mice. Genesis. 2008;46:163-166.
62. Feyerabend TB, Terszowski G, Tietz A, et al. Deletion of Notch1 converts pro-T cells to dendritic cells and promotes thymic B cells by cell-extrinsic and cell-intrinsic mechanisms. Immunity. 2009;30:67-79.
63. Lantz CS, Yamaguchi M, Oettgen HC, et al. IgE regulates mouse basophil Fc epsilon RI expression in vivo. J Immunol. 1997;158:2517-2521.
64. Sullivan BM, Locksley RM. Basophils: a nonredundant contributor to host immunity. Immunity. 2009;30:12-20.
65. Galli SJ, Franco CB. Basophils are back! Immunity. 2008;28:495-497.
66. Hedin H, Richter W, Messmer K, Renck H, Ljungstrom KG, Laubenthal H. Incidence, pathomechanism and prevention of dextran-induced anaphylactoid// anaphylactic reactions in man. Dev Biol Stand. 1980;48:179-189.
67. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995;125:348-355.
68. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
69. Umeda Y, Fukumoto Y, Miyauchi T, et al. Anaphylactic shock related to aprotinin induced by anti-aprotinin immunoglobulin G antibody alone; report of a case. Kyobu Geka. 2007;60:69-71.
70. Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol. 2005;174:7716-7724.
71. Martin TR, Galli SJ, Katona IM, Drazen JM. Role of mast cells in anaphylaxis. Evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice. J Clin Invest. 1989;83:1375-1383.
72. Takeishi T, Martin TR, Katona IM, Finkelman FD, Galli SJ. Differences in the expression of the cardiopulmonary alterations associated with anti-immunoglobulin E-induced or active anaphylaxis in mast cell-deficient and normal mice. Mast cells are not required for the cardiopulmonary changes associated with certain fatal anaphylactic responses. J Clin Invest. 1991;88:598-608.
73. Martin TR, Takeishi T, Katz HR, Austen KF, Drazen JM, Galli SJ. Mast cell activation enhances airway responsiveness to methacholine in the mouse. J Clin Invest. 1993;91:1176-1182.
74. d mice acquire anaphylactic responsiveness, but the congenic normal mice do not exhibit augmented responses. J Clin Invest. 1993;92:1639-1649.
75. Dombrowicz D, Flamand V, Miyajima I, Ravetch J V, Galli SJ, Kinet JP. Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains. J Clin Invest. 1997;99:915-925.
76. Hua X, Kovarova M, Chason KD, Nguyen M, Koller BH, Tilley SL. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med. 2007;204:117-128.
77. Olivera A, Mizugishi K, Tikhonova A, et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity. 2007;26:287-297.
78. Gri G, Piconese S, Frossi B, et al. CD4 + CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771-781.
79. Charles N, Watford WT, Ramos HL, et al. Lyn kinase controls basophil GATA-3 transcription factor expression and induction of Th2 cell differentiation. Immunity. 2009;30:533-543.
80. Schneider E, Petit-Bertron AF, Bricard R, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol. 2009;183:3591-3597.
81. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226-232.
82. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123: 680-686.
83. Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol. 2009;123:687-688.
84. Ring J, Darsow U. Idiopathic anaphylaxis. Curr Allergy Asthma Rep. 2002;2:40-45.
85. Iwaki S, Spicka J, Tkaczyk C, et al. Kit-and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. Cell Signal. 2008;20:195-205.
86. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753-763.
87. Ryan JJ, Spiegel S. The role of sphingosine-1-phosphate and its receptors in asthma. Drug News Perspect. 2008;21:89-96.
88. Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood. 2008;111:4193-4200.
89. Takizawa F, Adamczewski M, Kinet JP. Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as Fc gamma RII and Fc gamma RIII. J Exp Med. 1992;176:469-475.
90. Ujike A, Ishikawa Y, Ono M, et al. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med. 1999;189:1573-1579.
91. 125I-fibrin deposition in IgE-dependent immediate hypersensitivity reactions in mouse skin. Demonstration of the role of mast cells using genetically mast cell-deficient mice locally reconstituted with cultured mast cells. J Immunol. 1987;139:2605-2614.
92. Wershil BK, Wang ZS, Gordon JR, Galli SJ. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J Clin Invest. 1991;87:446-453.
93. Gordon JR, Galli SJ. Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the Fc epsilon RI. Role for mast cell-derived transforming growth factor beta and tumor necrosis factor alpha. J Exp Med. 1994;180:2027-2037.
94. Wershil BK, Furuta GT, Wang ZS, Galli SJ. Mast cell-dependent neutrophil and mononuclear cell recruitment in immunoglobulin E-induced gastric reactions in mice. Gastroenterology. 1996;110:1482-1490.
95. Furuta GT, Schmidt-Choudhury A, Wang MY, et al. Mast cell-dependent tumor necrosis factor alpha production participates in allergic gastric inflammation in mice. Gastroenterology. 1997;113:1560-1569.
96. Jawdat DM, Albert EJ, Rowden G, Haidl ID, Marshall JS. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol. 2004;173:5275-5282.
97. Silva SR, Casabuono A, Jacysyn JF, et al. Sialic acid residues are essential for the anaphylactic activity of murine IgG1 antibodies. J Immunol. 2008;181:8308-8314.
98. Latour S, Bonnerot C, Fridman WH, Daeron M. Induction of tumor necrosis factor-alpha production by mast cells via Fc gamma R. Role of the Fc gamma RIII gamma subunit. J Immunol. 1992;149:2155-2162.
99. Arimura A, Nagata M, Takeuchi M, Watanabe A, Nakamura K, Harada M. Active and passive cutaneous anaphylaxis in WBB6F1 mouse, a mast cell-deficient strain. Immunol Invest. 1990;19:227-233.
100. Hazenbos WL, Gessner JE, Hofhuis FM, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity. 1996;5:181-188.
101. Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol. 2008;38:489-499.
102. Dombrowicz D, Flamand V, Brigman KK, Koller BH, Kinet JP. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell. 1993;75:969-976.
103. Katz HR. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev. 2007;217:222-230.
104. Daheshia M, Friend DS, Grusby MJ, Austen KF, Katz HR. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J Exp Med. 2001;194:227-234.
105. Zabel BA, Nakae S, Zuniga L, et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008;205:2207-2220.
106. Maekawa A, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem. 2002;277:20820-20824.
107. Jacoby W, Cammarata P V, Findlay S, Pincus SH. Anaphylaxis in mast cell-deficient mice. J Invest Dermatol. 1984;83:302-304.
108. v mice. Int Arch Allergy Appl Immunol. 1986;80:85-94.
109. d genotypes. Exp Cell Biol. 1987;55:63-68.
110. Martin TR, Ando A, Takeishi T, Katona IM, Drazen JM, Galli SJ. Mast cells contribute to the changes in heart rate, but not hypotension or death, associated with active anaphylaxis in mice. J Immunol. 1993;151:367-376.
111. v mice. Cell Mol Life Sci. 1997;53:663-666.
112. Cara DC, Ebbert KV, McCafferty DM. Mast cell-independent mechanisms of immediate hypersensitivity: a role for platelets. J Immunol. 2004;172:4964-4971.
113. Choi IH, Shin YM, Park JS, et al. Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice. J Exp Med. 1998;188:1587-1592.
114. Choi IW, Kim YS, Kim DK, et al. Platelet-activating factor-mediated NF-kappaB dependency of a late anaphylactic reaction. J Exp Med. 2003;198:145-151.
115. Park JS, Choi IH, Lee DG, et al. Anti-IL-4 monoclonal antibody prevents antibiotics-induced active fatal anaphylaxis. J Immunol. 1997;158:5002-5006.
116. Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T. IgE-mediated activation of NK cells through Fc gamma RIII. J Immunol. 2003;170:3054-3058.
117. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-193.
118. Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu Rev Med. 2009;60:261-277.
119. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986-993.
120. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380-384.
121. Sun J, Arias K, Alvarez D, et al. Impact of CD40 ligand, B cells, and mast cells in peanut-induced anaphylactic responses. J Immunol. 2007;179:6696-6703.
122. Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009;123:342-351.
123. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest. 1980;66:1072-1080.
124. van der Linden PW, Hack CE, Kerckhaert JA, Struyvenberg A, van der Zwan JC. Preliminary report: complement activation in wasp-sting anaphylaxis. Lancet. 1990;336:904-906.
125. v mice by bone marrow transplantation. J Clin Invest. 1991;87:687-693.
126. Brandt EB, Strait RT, Hershko D, et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest. 2003;112:1666-1677.
127. Forbes EE, Groschwitz K, Abonia JP, et al. IL-9-and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med. 2008;205:897-913.
128. Hauber HP, Bergeron C, Hamid Q. IL-9 in allergic inflammation. Int Arch Allergy Immunol. 2004;134:79-87.
129. Redegeld FA, van der Heijden MW, Kool M, et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med. 2002;8:694-701.
130. Kraneveld AD, Kool M, van Houwelingen AH, et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci USA. 2005;102:1578-1583.
131. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-836.
132. De Carolis C, Perricone R, De Sanctis G, Fontana L. Complement activation by Hymenoptera venom allergenic extracts. J Allergy Clin Immunol. 1982;70:219-220.
133. von Zabern I, Przyklenk H, Nolte R, Vogt W. Effect of different penicillin derivatives on complement components in human serum. Int Arch Allergy Appl Immunol. 1984;75:164-172.
134. Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I. Regulation of mast cell activation by complement-derived peptides. Immunol Lett. 2004;92:39-42.
135. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415-1418.
136. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-1445.
137. Beck LA, Marcotte G V, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004;114:527-530.
138. Matsuda K, Piliponky AM, Nakae S, Kawakami T, Tsai M, Galli SJ. IgE enhances human mast cell survival and chemokine production: IL-4 augments the secretory response. J Allergy Clin Immunol. 2005;116:1357-1363.
139. Asai K, Kitaura J, Kawakami Y, et al. Regulation of mast cell survival by IgE. Immunity. 2001;14:791-800.
140. Kalesnikoff J, Huber M, Lam V, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. 2001;14:801-811.
141. Kitaura J, Song J, Tsai M, et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA. 2003;100:12911-12916.
142. Kohno M, Yamasaki S, Tybulewicz VL, Saito T. Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood. 2005;105:2059-2065.
143. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks catinduced allergy. Nat Med. 2005;11:446-449.
144. Kalesnikoff J, Galli SJ. Nipping cat allergy with fusion proteins. Nat Med. 2005;11:381-382.
145. Mertsching E, Bafetti L, Hess H, et al. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J Allergy Clin Immunol. 2008;121:441-447 e445.
146. Bachelet I, Munitz A, Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol. 2006;117:1314-1320.
147. Ong CJ, Ming-Lum A, Nodwell M, et al. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood. 2007;110:1942-1949.
148. Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol. 2004;114:321-327.
149. Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol. 2004;173:5247-5257.
150. Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 2006;176:2238-2248.
151. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol. 2006;6:476-481.
152. MacGlashan D Jr, Lavens-Phillips S, Katsushi M. IgE-mediated desensitization in human basophils and mast cells. Front Biosci. 1998;3:d746-756.
153. MacGlashan D Jr. Desensitization of IgE-mediated IL-4 release from human basophils. J Leukoc Biol. 1998;63:59-67.
154. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol. 2005;138:29-39.
155. Plewako H, Wosinska K, Arvidsson M, et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol. 2006;141:346-353.
156. Nagao M, Hiraguchi Y, Hosoki K, et al. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2008;146 Suppl 1:47-53.
157. MacGlashan D Jr, Vilarino N. Polymerization of actin does not regulate desensitization in human basophils. J Leukoc Biol. 2009;85:627-637.
158. Ishizaka T, Sterk AR, Daeron M, Becker EL, Ishizaka K. Biochemical analysis of desensitization of mouse mast cells. J Immunol. 1985;135:492-501.
159. Shalit M, Levi-Schaffer F. Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy. 1995;25:896-902.
160. Rubinchik E, Shalit M, Levi-Schaffer F. Responsiveness of human skin mast cells to repeated activation: an in vitro study. Allergy. 1998;53:14-19.
161. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005;94:575-580.